ClinicalTrials.gg
CompletedNCT01106430Updated Jun 11, 2021Results posted

Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate

A Phase 3 interventional study of Lisdexamfetamine Dimesylate and Atomoxetine Hydrochloride in Attention-Deficit/Hyperactivity Disorder, sponsored by Shire. Completed at 64 sites in 10 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-06-11.

Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
267
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity — 1 open to participants now, 1 under way, none of them phase 3. lisdexamfetamine · Attention Deficit Disorder with Hyperactivity.

Enrollment
12th of 51
267 · median 48
Started
2010
with 4 others
Phase 3
15 of 51
none open now
Registered
27th of 51
by date
Lead sponsor
18 of 51
Shire

Among the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, this one is the 12th largest by enrollment, is one of 5 that started in 2010, is one of 15 in phase 3, and was the 27th registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

1 of the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About lisdexamfetamine

lisdexamfetamine: first FDA approval 2007 (VYVANSE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, or all of them as a file.
02

Study summary

This study will evaluate how long it takes for ADHD symptoms to improve in subjects who are judged by the Investigator to have had an inadequate response to methylphenidate therapy. The study will also test the safety of Lisdexamfetamine Dimesylate and how well it works.

03

Conditions studied

  • Attention-Deficit/Hyperactivity Disorder

Keywords

  • ADHD
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has had an historical or current inadequate response to methylphenidate (MPH) treatment. Inadequate response includes but is not limited to the presence of some residual symptoms, with associated impairment inadequate duration of action and/or variability of symptom control, and/or Investigator feels that the subject may derive benefit from an alternative drug treatment to MPH therapy.
  • Subject is a male or female aged 6-17 years inclusive at the time of consent
  • Subject must meet , fourth edition. - Text Revision (DSM IV TR) criteria for a primary diagnosis of ADHD based on a detailed psychiatric evaluation
  • Subject must have a baseline ADHD-RS-IV total score 28.

Exclusion criteria

Exclusion Criteria:

  • Subject has taken more than 1 MPH treatment (for example, 2 or more different MPH treatments). Examples include but are not limited to RITALIN immediate release (IR) and EQUASYM IR; MEDIKINET IR and CONCERTA; RITALIN long-acting LA and CONCERTA. Note: this does not include subjects who have taken IR MPH for dose titration on a short-term basis (for example, £4 weeks) with an adequate response
  • In the Investigator's judgement, subject has failed to respond to more than 1 previous course(s) of MPH treatment. Failure to respond includes worsening of symptoms or no change/minimal improvement of symptoms.
  • Subject has previously been exposed to STRATTERA or to amphetamine therapy
  • Subject has previously demonstrated intolerable side effects to 1 MPH treatment which limited titration to acceptable efficacy or that required a decrease in dose resulting in unacceptable tolerability and/or efficacy
  • Subject has a current, controlled (requiring a restricted medication) or uncontrolled, comorbid psychiatric diagnosis with significant symptoms such as any severe comorbid Axis II disorder or severe Axis I disorder or other symptomatic manifestations, such as agitated states, marked anxiety, or tension that, in the opinion of the examining physician, will contraindicate treatment with SPD489 or STRATTERA or confound efficacy or safety assessments.
  • Subject has a conduct disorder. Oppositional Defiant Disorder is not exclusionary.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
267 participants (actual)

Study arms

  • Experimental
    Lisdexamfetamine Dimesylate

    Drug: Lisdexamfetamine Dimesylate

  • Active comparator
    Atomoxetine Hydrochloride

    Drug: Atomoxetine Hydrochloride

Interventions

06

What researchers measure

Primary outcomes

  1. Time to First Response

    Time to first response was defined as a Clinical Global Impression-Improvement (CGI-I) value of 1 (very much improved) or 2 (much improved) first recorded following first dose of investigational product. CGI-I consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).

    Time frame: 9 weeks

Secondary outcomes

  1. Percent of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores - Last Observation Carried Forward (LOCF)

    Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.

    Time frame: 9 weeks

  2. Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-Fourth Edition (ADHD-RS-IV) Total Score at 9 Weeks - LOCF

    ADHD-RS-IV consists of 18 items scored on a 4-point scale from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. A decrease in score indicates an improvement in ADHD symptomology.

    Time frame: Baseline and 9 weeks

  3. Change From Baseline in the Weiss Functional Impairment Rating Scale - Parent Report (WFIRS-P) Global Score at Up to 9 Weeks

    The WFIRS-P is a 50-item scale with each item scored from 0 (never/not at all) to 3 (very often/very much). Mean scores range from 0 to 3. Higher scores indicate greater functional impairment.

    Time frame: Baseline and up to 9 weeks

  4. Health Utilities Index-2 (HUI-2) Scores at Up to 9 Weeks

    HUI is used to describe health status and to obtain utility scores by collecting data using one or more questionnaires in formats selected to match the specific study design criteria. Scoring ranges from 0.00 (dead) to 1.00 (perfect health). Higher scores represent better health status.

    Time frame: up to 9 weeks

  5. Change From Baseline in Brief Psychiatric Rating Scale for Children (BPRS-C) Total Score at Up to 9 Weeks

    The BPRS-C characterizes psychopathology. A total of 21 items are rated on a scale from 0 (not present) to 6 (extremely severe) with a total score ranging from 0 to 126. A decrease in score indicates a reduction in psychopathology.

    Time frame: Baseline and up to 9 weeks

  6. Columbia-Suicide Severity Rating Scale (C-SSRS)

    C-SSRS is a semi-structured interview that captures the occurence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The assessment is done by the nature of the responses, not by a numbered scale.

    Time frame: 9 weeks

  7. Udvalg for Kliniske Undersogelser Side Effect Rating Scale - Clinician (UKU-SERS-Clin) With Side Effects Scores >=1

    UKU-SERS-Clin is composed of 48 items each of which asks about a single side effect. Each side effect is rated based on a 4-point scale ranging from 0 (no or doubtful presence) to 3 (the least favorable rating). The rating is independent of whether the symptom is regarded as related to the investigational product.

    Time frame: 9 weeks

07

Results

Posted Jun 24, 2013

Participant flow

Participant flow — Overall Study
MilestoneLisdexamfetamine DimesylateAtomoxetine Hydrochloride
Started133134
Completed100101
Not completed3333
Withdrew: Adverse event810
Withdrew: Lack of efficacy213
Withdrew: Lost to follow-up51
Withdrew: Early termination requested by sponsor10
Withdrew: Moved out of state01
Withdrew: Refused to take medication01
Withdrew: Noncompliance01
Withdrew: Hard time swallowing the pills10
Withdrew: Previous use of marijuana10
Withdrew: Protocol violation72
Withdrew: Withdrawal by subject84

Outcome measures

PrimaryTime to First Response

Time to first response was defined as a Clinical Global Impression-Improvement (CGI-I) value of 1 (very much improved) or 2 (much improved) first recorded following first dose of investigational product. CGI-I consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).

Time frame:
9 weeks
Reported as:
Median · Days
Time to First Response
DaysLisdexamfetamine DimesylateAtomoxetine Hydrochloride
Time to First Response12.0 (8.0 to 16.0)21.0 (15.0 to 23.0)
Statistical analysis
  • Lisdexamfetamine Dimesylate vs Atomoxetine Hydrochloride · Peto-Peto-Prentice Wilcoxon Test · p = =0.001
SecondaryPercent of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores - Last Observation Carried Forward (LOCF)

Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.

Time frame:
9 weeks
Reported as:
Number · percentage of participants
Percent of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores - Last Observation Carried Forward (LOCF)
percentage of participantsLisdexamfetamine DimesylateAtomoxetine Hydrochloride
Percent of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores - Last Observation Carried Forward (LOCF)81.763.6
Statistical analysis
  • Lisdexamfetamine Dimesylate vs Atomoxetine Hydrochloride · Cochran-Mantel-Haenszel · p = 0.001 · Mean difference (final values): 18.1 · 95% CI 7.5 to 28.7
SecondaryChange From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-Fourth Edition (ADHD-RS-IV) Total Score at 9 Weeks - LOCF

ADHD-RS-IV consists of 18 items scored on a 4-point scale from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. A decrease in score indicates an improvement in ADHD symptomology.

Time frame:
Baseline and 9 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-Fourth Edition (ADHD-RS-IV) Total Score at 9 Weeks - LOCF
units on a scaleLisdexamfetamine DimesylateAtomoxetine Hydrochloride
Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-Fourth Edition (ADHD-RS-IV) Total Score at 9 Weeks - LOCF-26.1 ± 1.16-19.7 ± 1.13
Statistical analysis
  • Lisdexamfetamine Dimesylate vs Atomoxetine Hydrochloride · ANCOVA · p = <0.001 · Difference in ls means: -6.5 · 95% CI -9.3 to -3.6
SecondaryChange From Baseline in the Weiss Functional Impairment Rating Scale - Parent Report (WFIRS-P) Global Score at Up to 9 Weeks

The WFIRS-P is a 50-item scale with each item scored from 0 (never/not at all) to 3 (very often/very much). Mean scores range from 0 to 3. Higher scores indicate greater functional impairment.

Time frame:
Baseline and up to 9 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Weiss Functional Impairment Rating Scale - Parent Report (WFIRS-P) Global Score at Up to 9 Weeks
units on a scaleLisdexamfetamine DimesylateAtomoxetine Hydrochloride
Change From Baseline in the Weiss Functional Impairment Rating Scale - Parent Report (WFIRS-P) Global Score at Up to 9 Weeks-0.35 ± 0.034-0.27 ± 0.032
Statistical analysis
  • Lisdexamfetamine Dimesylate vs Atomoxetine Hydrochloride · ANCOVA · p = 0.046 · Difference in ls means: -0.09 · 95% CI -0.17 to -0.00
SecondaryHealth Utilities Index-2 (HUI-2) Scores at Up to 9 Weeks

HUI is used to describe health status and to obtain utility scores by collecting data using one or more questionnaires in formats selected to match the specific study design criteria. Scoring ranges from 0.00 (dead) to 1.00 (perfect health). Higher scores represent better health status.

Time frame:
up to 9 weeks
Reported as:
Mean · units on a scale
Health Utilities Index-2 (HUI-2) Scores at Up to 9 Weeks
units on a scaleLisdexamfetamine DimesylateAtomoxetine Hydrochloride
Health Utilities Index-2 (HUI-2) Scores at Up to 9 Weeks0.920 ± 0.09610.922 ± 0.0937
SecondaryChange From Baseline in Brief Psychiatric Rating Scale for Children (BPRS-C) Total Score at Up to 9 Weeks

The BPRS-C characterizes psychopathology. A total of 21 items are rated on a scale from 0 (not present) to 6 (extremely severe) with a total score ranging from 0 to 126. A decrease in score indicates a reduction in psychopathology.

Time frame:
Baseline and up to 9 weeks
Reported as:
Mean · units on a scale
Change From Baseline in Brief Psychiatric Rating Scale for Children (BPRS-C) Total Score at Up to 9 Weeks
units on a scaleLisdexamfetamine DimesylateAtomoxetine Hydrochloride
Change From Baseline in Brief Psychiatric Rating Scale for Children (BPRS-C) Total Score at Up to 9 Weeks-10.7 ± 9.27-7.9 ± 9.07
SecondaryColumbia-Suicide Severity Rating Scale (C-SSRS)

C-SSRS is a semi-structured interview that captures the occurence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The assessment is done by the nature of the responses, not by a numbered scale.

Time frame:
9 weeks
Reported as:
Number · participants
Columbia-Suicide Severity Rating Scale (C-SSRS)
participantsLisdexamfetamine DimesylateAtomoxetine Hydrochloride
Suicidal ideation00
Suicidal behavior00
SecondaryUdvalg for Kliniske Undersogelser Side Effect Rating Scale - Clinician (UKU-SERS-Clin) With Side Effects Scores >=1

UKU-SERS-Clin is composed of 48 items each of which asks about a single side effect. Each side effect is rated based on a 4-point scale ranging from 0 (no or doubtful presence) to 3 (the least favorable rating). The rating is independent of whether the symptom is regarded as related to the investigational product.

Time frame:
9 weeks
Reported as:
Number · participants
Udvalg for Kliniske Undersogelser Side Effect Rating Scale - Clinician (UKU-SERS-Clin) With Side Effects Scores >=1
participantsLisdexamfetamine DimesylateAtomoxetine Hydrochloride
Weight Loss4619
Reduced Duration of Sleep2916
Asthenia/Lassitude/Increased Fatigability2529
Tension/Inner Unrest2022
Nausea/Vomiting1926
Sleepiness/Sedation1635
Reduced Salivation166
Headache-Tension Headache1517
Concentration Difficulties7592
Failing Memory1021
Depression610
Increased Duration of Sleep1212
Increased Dream Activity38
Emotional Indifference1210
Dystonia01
Rigidity01
Hypokinesia/Akinesia10
Hyperkinesia Logic23
Tremor31
Akathisia02
Paraesthesias10
Accomodation Disturbances02
Increased Salivation12
Diarrhea69
Constipation95
Micturition Disturbances01
Polyuria/Polydipsia32
Orthostatic Dizziness109
Palpitations/Tachycardia15
Increased Tendency to Sweating35
Rash-Morbiliform01
Rash-Petechial10
Rash-Urticarial11
Rash-Cannot be Classified12
Pruritus47
Weight Gain10
Headache-Migraine22
Headache-Other Forms1110

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lisdexamfetamine Dimesylate—0/128 (0%)92/128 (71.9%)
Atomoxetine Hydrochloride—0/134 (0%)95/134 (70.9%)
Most frequent other events
Showing 10 of 17
Most frequent other events
EventLisdexamfetamine DimesylateAtomoxetine Hydrochloride
DECREASED APPETITEMetabolism and nutrition disorders33/12814/134
WEIGHT DECREASEDInvestigations28/1289/134
HEADACHENervous system disorders17/12822/134
NAUSEAGastrointestinal disorders16/12821/134
SOMNOLENCENervous system disorders4/12816/134
INSOMNIAPsychiatric disorders15/1288/134
FATIGUEGeneral disorders12/12814/134
VOMITINGGastrointestinal disorders6/12813/134
ABDOMINAL PAIN UPPERGastrointestinal disorders3/12810/134
DIARRHOEAGastrointestinal disorders2/1289/134

Baseline characteristics

Safety Population was used for baseline characteristics (n = 262). Defined as all subjects who were randomized and who had taken at least 1 dose of investigational product. Five randomized subjects did not take any investigational product.

Age, Continuous
Age, Continuous(Years)Lisdexamfetamine DimesylateAtomoxetine HydrochlorideTotal
Mean10.9 ± 3.0110.4 ± 2.8410.6 ± 2.93
Age, Customized
Age, Customized(Participants)Lisdexamfetamine DimesylateAtomoxetine HydrochlorideTotal
13 - 17 years343468
6 - 12 years94100194
Sex: Female, Male
Sex: Female, Male(Participants)Lisdexamfetamine DimesylateAtomoxetine HydrochlorideTotal
Female343165
Male94103197
Region of Enrollment
Region of Enrollment(Participants)Lisdexamfetamine DimesylateAtomoxetine HydrochlorideTotal
BELGIUM022
CANADA171835
GERMANY202242
HUNGARY101020
ITALY101
POLAND011
SPAIN121022
SWEDEN336
UNITED STATES7068138
08

Study locations

64 sites
  • Harmonex Neuroscience Research, Inc
    Dothan, Alabama 36303, United States
  • Clinical Study Centers, LLC
    Little Rock, Arkansas 72205, United States
  • Shanti Clinical Trials
    Colton, California 92324, United States
  • Psychiatric Centers at San Diego Feighner Research
    San Diego, California 92108, United States
  • Elite Clinical Trials, Inc.
    Wildomar, California 92595, United States
  • Sarkis Clinical Trials
    Gainesville, Florida 32607, United States
  • Amedica Research Institute, Inc.
    Hialeah, Florida 33013, United States
  • Fidelity Clinical Research, Inc.
    Lauderhill, Florida 33319, United States
  • Clinical Neuroscience Solutions, INC
    Orlando, Florida 32806, United States
  • Northwest Behavioral Research Center
    Roswell, Georgia 30076, United States
  • Capstone Clinical Research
    Libertyville, Illinois 60048, United States
  • Baber Psychiatric Associates
    Naperville, Illinois 60563, United States
  • Clinco
    Terre Haute, Indiana 47802, United States
  • Heartland Research Associates, LLC
    Wichita, Kansas 67207, United States
  • Four Rivers Clinical Research, Inc
    Paducah, Kentucky 42003, United States
  • Louisianna Research Associates
    New Orleans, Louisiana 70114, United States
  • Office of Marc Hertzman, MD, PC
    Rockville, Maryland 20852, United States
  • Rochester Center for Behavioral Medicine
    Rochester Hills, Michigan 48307, United States
  • Midwest Research Group/Saint Charles Psychiatric Associates
    Saint Charles, Missouri 63301, United States
  • Premier Psychiatric Research Institute, LLC
    Lincoln, Nebraska 68526, United States
  • Center for Psychiatry and Behavioral Medicine, Inc.
    Las Vegas, Nevada 89128, United States
  • Children's Specialized Hospital
    Toms River, New Jersey 08755, United States
  • Richmond Behavioral Associates
    Staten Island, New York 10312, United States
  • Triangle Neuropsychiatry, PLLC
    Durham, North Carolina 27707, United States
  • Innovis Health
    Fargo, North Dakota 58103, United States
  • IPS Research Company
    Oklahoma City, Oklahoma 73103, United States
  • Cyn3rgy Research
    Gresham, Oregon 97030, United States
  • CRI Worldwide, LLC Kirkbride Division
    Philadelphia, Pennsylvania 19139, United States
  • Future Search Clinical Trials
    Austin, Texas 78731, United States
  • Red Oak Psychiatry Association, PA
    Houston, Texas 77090, United States
  • Western Clinical Investigations
    Lubbock, Texas 79423, United States
  • Cerebral Research, LLC
    San Antonio, Texas 78247, United States
  • Lifetree Clinical Research
    Salt Lake City, Utah 84106, United States
  • Eastside Therapeutic Resource
    Kirkland, Washington 98033, United States
  • ZiekenhuisNetwerk Antwerpen
    Hoboken, Antwerpen 2660, Belgium
  • Universitair Ziekenhuis Gasthuisberg
    Leuven, Flemish Brabant 3000, Belgium
  • Child and Adolescent Centre
    Edmonton, Alberta T6H 1P7, Canada
  • Centre for Anxiety Attention Deficit and Trauma
    Hamilton, Ontario L8S 1B7, Canada
  • AK Karan Holdings, Ltd.
    Oakville, Ontario L6J 0B2, Canada
  • The Kids Clinic
    Whitby, Ontario L1N 8M7, Canada
  • University of Saskatchewan
    Saskatoon, Saskatchewan S7N 0W8, Canada
  • Albert-Ludwigs-Universitat Freiburg
    Freiburg, Baden-Wuerttemberg 79104, Germany
  • Zentralinstitut für Seelische Gesundheit Mannheim
    Mannheim, Baden-wuerttemberg 68159, Germany
  • Schwerpunktpraxis für Entwicklung und Lernen
    Bamberg, Bayern 96047, Germany
  • Medizinisches Studienzentrum Würzburg
    Wurzburg, Bayern 97070, Germany
  • Klinikum Frankfurt/Oder
    Frankfurt/Oder, Brandenburg 15236, Germany
  • Praxis Dr. Wolff
    Hagen, Nordrhein-Westfalen 58093, Germany
  • Szegedi Tudományegyetem Gyermek es lfjusagpszichlatrlai Osztaly
    Szeged, Csongrad 6720, Hungary
  • Vadaskert Korhaz es Szakambulancia Gyermek es lfjusagpszichiatria
    Budapest, Hungary
  • Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza
    Gyula, 5700, Hungary
  • Gyermek- es lfjusagpszichiatriai Szakrendeles es Gondozo
    Pecs, Hungary
  • Azienda Ospedaliero-Universitaria di Cagliari
    Cagliari, 9124, Italy
  • Katedra i Klinika Psychiatarii
    Bydgoszcz, Kujawsko-Pomorskie 85-096, Poland
  • Samodzielny Publiczny Dzieciecy Szpital Kliniczny
    Warszawa, Mazowieckie 00-576, Poland
  • Hospital Son Llàtzer
    Palma de Mallorca, Baleares 7198, Spain
  • Hospital Sant Joan de Deu
    Esplugues De Llobregat, Barcelona 08950, Spain
  • Hospital Marítimo, Unidad de Salud Mental Infanto-Juvenil (USMI-J
    Torremolinos, Malaga 29620, Spain
  • Hospital Universitario de Canarias
    San Cristobal De La laguna, Santa Cruz De Tenerife 38320, Spain
  • Complejo Hospitalario Universitario de Badajoz
    Badajoz, 6010, Spain
  • Hospital Clinic i Provincial de Barcelona
    Barcelona, 8036, Spain
  • Drottning Silvias Barnsjukhus
    Goteborg, 411 18, Sweden
  • Astrid Lindgren Children's Hospital/Karolinska University Hospital
    Stockholm, 141 86, Sweden
  • Basildon Hospital
    Basildon, Essex SS16 5NL, United Kingdom
  • Tayside Children's Hospital
    Dundee, Scotland DD1 9SY, United Kingdom
09

References and documents

Publications

  • Dittmann RW, Cardo E, Nagy P, Anderson CS, Bloomfield R, Caballero B, Higgins N, Hodgkins P, Lyne A, Civil R, Coghill D. Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study. CNS Drugs. 2013 Dec;27(12):1081-92. doi: 10.1007/s40263-013-0104-8. PubMed 23959815 ↗
  • Nagy P, Hage A, Coghill DR, Caballero B, Adeyi B, Anderson CS, Sikirica V, Cardo E. Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate. Eur Child Adolesc Psychiatry. 2016 Feb;25(2):141-9. doi: 10.1007/s00787-015-0718-0. Epub 2015 May 22. PubMed 25999292 ↗
  • Dittmann RW, Cardo E, Nagy P, Anderson CS, Adeyi B, Caballero B, Hodgkins P, Civil R, Coghill DR. Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder. CNS Drugs. 2014 Nov;28(11):1059-69. doi: 10.1007/s40263-014-0188-9. PubMed 25038977 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2010 to primary completion in Jul 2012, 24 months.

Results were first posted in Jun 2013, 11 months after primary completion.

Of 66 industry-sponsored phase 3 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 24 months is above that.

Counting every sponsor, half of 80 studies reached it within 14 months; a quarter within 7 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2010
First posted
Apr 19, 2010
StartActual
Jun 28, 2010
Primary completionActual
Jul 19, 2012
CompletionActual
Jul 19, 2012
Results first posted
Jun 24, 2013
Last update
Jun 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01106430
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Apr 19, 2010
Start date
Jun 28, 2010
Primary completion
Jul 19, 2012
Completion
Jul 19, 2012
Results posted
Jun 24, 2013
Last update
Jun 11, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisdexamfetamine

Start the discussion